Cytokinetics is a late-stage biopharmaceutical company focused on discovering and developing potential medicines to improve healthspans in
diseases of impaired muscle function
Founded in 1997 by pioneers in muscle biology, we leverage unparalleled expertise to engineer compounds that
target the sarcomere
Cytokinetics has product research and development
partnerships that power innovation and discovery
We are inspired by the patients, caregivers and advocates in the communities we serve who
fearlessly fight every day
Empowering the future
Strategic initiative to deepen and expand our pipeline
driven potential therapies
for diseases characterized by
compromised muscle function,
muscle weakness and fatigue
Our areas of focus
- Heart Failure
- Hypertrophic Cardiomyopathy
- Amyotrophic Lateral Sclerosis
- Spinal Muscular Atrophy
This information is intended for healthcare providers only. Compounds are investigational.
Inclusion in this display does not imply regulatory approval for these compounds in any indication.
Information about all Cytokinetics-sponsored trials can be found at cytokinetics.com/clinical-trials/
You are now exiting the Cytokinetics exhibit for the AHA Scientific Sessions 2020 Virtual Meeting. The link you’ve selected will take you to an external website.